Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2025-524722-17-00
2025-524722-17-00RecruitingPhase 4

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Region Skane2 sites in 1 country40 target enrollmentStarted: August 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Enrollment
40
Locations
2
Primary Endpoint
Change in myocardial perfusion reserve (MPR) (averaged values across all hypertrophied myocardial segments without significant LGE) from baseline to 2 years after initiation of treatment.
Study OverviewEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

to investigate acute, sub-acute and chronic hemodynamic and physiological effects of treatment with mavacamten in patients with oHCM using state-of-the art cardiovascular magnetic resonance (CMR) imaging.

Eligibility Criteria

Ages
18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The subject has given their written consent to participate in the trial.
  • •Age ≥ 18 years
  • •Diagnosis of oHCM with unexplained LV hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥15 mm
  • •Eligible for on-label mavacamten therapy per Swedish prescribing information.
  • •Left ventricular outflow tract (LVOT) ≥ 50 mmHg at rest, during Valsalva or post-exercise.
  • •Left ventricular ejection fraction ≥ 55%
  • •New York Heart Association (NYHA) class II or III symptoms.
  • •Participants who are capable of becoming pregnant must not be pregnant or lactating and, if sexually active, must use effective birth control methods (see section 7.4) from the Screening visit through 6 months after the last dose of mavacamten.

Exclusion Criteria

  • •Presence or planned implantation of electronic cardiac devices such as ICD or pacemaker
  • •Reduced kidney function with estimated GFR <30 ml/min/1.73m2
  • •Severe impairment of liver function (Child-Pugh class C) or if there is an alanine aminotransferase or aspartate aminotransferase result, the value must be <3 × the upper limit of the laboratory reference range
  • •Unable to comply with the study requirements
  • •Unable to perform CMR exams
  • •Body mass index ≥ 40kg/m2
  • •Participation or recent participation in a clinical trial with an investigational medicinal product within 30 days.
  • •Previous participation in this trial
  • •Known or suspected allergies against any product included in the trial
  • •Pregnancy (positive p-hCG test at screening), breastfeeding, or planned pregnancy
  • •Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of participation in the trial
  • •History of or planned septal reduction therapy (surgical myectomy or percutaneous alcohol ablation) during trial period
  • •Treatment or disease which, according to the investigator, can affect treatment or trial results
  • •Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy
  • •Has paroxysmal, intermittent atrial fibrillation with atrial fibrillation present per the investigator’s evaluation of the participant’s ECG at the time of Screening
  • •Has permanent atrial fibrillation
  • •Current treatment (within 14 days prior to screening) or planned treatment during the study with: (a) a strong CYP3A4 inhibitor in participants with poor or unknown CYP2C19 metaboliser phenotype; (b) the simultaneous combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor; (c) strong inducers of both CYP2C19 and CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, St. John's Wort); or (d) omeprazole or esomeprazole.
  • •Has documented obstructive coronary artery disease (>70% stenosis in one or more epicardial coronary arteries) or history of myocardial infarction
  • •Has known moderate or severe (as per investigator’s judgment) aortic valve stenosis at Screening
  • •Has any acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study

Arms & Interventions

CAMZYOS 10 mg hard capsules

Test

Intervention: CAMZYOS 10 mg hard capsules (Drug)

Outcomes

Primary Outcomes

Change in myocardial perfusion reserve (MPR) (averaged values across all hypertrophied myocardial segments without significant LGE) from baseline to 2 years after initiation of treatment.

Change in myocardial perfusion reserve (MPR) (averaged values across all hypertrophied myocardial segments without significant LGE) from baseline to 2 years after initiation of treatment.

Secondary Outcomes

  • Change in MPR from BL to 12 weeks
  • Change in MPR from BL to 1 year
  • Changes in T1, T2 and extracellular volume (ECV) mapping from BL to 12 w, 1 year and 2 years
  • Change in LGE extent from BL to 12 w, 1 year and 2 years
  • Change in stroke work, ventricular efficiency, contractility, and arterial elastance assessed by P-V-loop-analysis from BL to 12 w, 1 year and 2 years
  • Change in kinetic energy and regional pressure gradients assessed by 4D flow-analysis from BL to 12 w, 1 year and 2 years
  • Changes in myocardial mass and left atrial volume assessed by standard CMR from BL to 12 w, 1 year and 2 years

Investigators

Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

Oscar Braun

Scientific

Region Skane

Study Sites (2)

Loading locations...

Similar Trials

Not yet recruiting
Phase 3 4
Comparison of effectiveness and hemodynamic stability of making patient sit for 10 mins versus making patient supine directly after subarachnoid block using Levobupivacaine with Fentanyl as an adjunct in Transurethral resection of prostate TURP surgery A randomised comparative study
CTRI/2024/12/077685GMERS Hospital60
Not yet recruiting
Phase 4
A Study Comparing Split Dose And Single Dose Spinal Anaesthesia In Infraumbilical Abdominal Surgeries.
CTRI/2025/08/093735Mounisha SV110
Recruiting
Phase 3 4
Comparing effects of various adjuvants added to anaesthetic agent in patients undergoing lower limb surgery under a combination of Spinal Anaesthesia and lumbar and sacral plexus blocks
CTRI/2024/12/077716Vikhe Patil Institute of Medical Sciences60
Not yet recruiting
Not Applicable
A study to compare the immediate and long term effects of foam roller and myofascial release on heel pain, improving movement and decreasing pain sensitivity in individuals with planter fasciitis.
CTRI/2026/02/10504730
Not yet recruiting
Phase 3
Anaylsis of hemodynamic responses during tracheal intubation by neuromuscular block monitored versus clinical assessment guided tracheal intubation
CTRI/2026/01/101935Dr Neelu Panghal70